A 35-month remission in a single patient is shedding light on a rare and confusing leukemia diagnosis. The case involved a person with Philadelphia chromosome-positive leukemia, a type of blood cancer. Doctors treated them with a tyrosine kinase inhibitor combined with chemotherapy. The patient achieved complete remission and maintained a deep molecular response for nearly three years.
The case also prompted a review of existing literature. The goal was to help doctors distinguish between two conditions that look alike under the microscope: chronic myeloid leukemia in blast crisis and a rare form of acute leukemia called Ph+ acute megakaryoblastic leukemia. This distinction matters because treatment approaches differ.
The review found that CML presenting with megakaryoblastic blast crisis is very rare, occurring in less than 3% of all CML cases. But because this is a single case report, the findings are not proof that this treatment will work for everyone. More research is needed to confirm the approach.
